| Pharmaceutical Information |
| Drug Name |
Cobimetinib |
| Drug ID |
BADD_D00513 |
| Description |
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. |
| Indications and Usage |
For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EE02 |
| DrugBank ID |
DB05239
|
| KEGG ID |
D10405
|
| MeSH ID |
C574276
|
| PubChem ID |
16222096
|
| TTD Drug ID |
D0FJ9I
|
| NDC Product Code |
50242-717 |
| UNII |
ER29L26N1X
|
| Synonyms |
cobimetinib | (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone | Cotellic | GDC-0973 | XL518 |
|
| Chemical Information |
| Molecular Formula |
C21H21F3IN3O2 |
| CAS Registry Number |
934660-93-2 |
| SMILES |
C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Acute kidney injury | 20.01.03.016 | 0.000168% | | |
|
|
|
